Earnings Call Summary | Omeros(OMER.US) Q4 2023 Earnings Conference
Earnings Call Summary | Omeros(OMER.US) Q4 2023 Earnings Conference
The following is a summary of the Omeros Corporation (OMER) Q4 2023 Earnings Call Transcript:
以下是歐美羅斯公司（OMER）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Omeros reported a Q4 2023 net loss of $9.1 million, or $0.15 per share, compared to a net loss of $37.8 million, or $0.60 per share, in Q3 2023. The net income for Q4 2022 was $128.7 million, or $2.05 per share.
The net loss for the full year 2023 was $117.8 million, or $1.88 per share, compared to a net income of $47.4 million, or $0.76 per share, in 2022.
Cash influx from operations for the year 2023 was $74.7 million.
The company had cash and investments totaling $172 million at the end of 2023. An additional expected royalty of $116 million from DRI in February 2024 could boost total cash and investments to $230 million by March 2024.
Omeros報告稱，2023年第四季度淨虧損910萬美元，合每股虧損0.15美元，而2023年第三季度的淨虧損爲3,780萬美元，合每股虧損0.60美元。2022年第四季度的淨收入爲1.287億美元，合每股2.05美元。
2023年全年的淨虧損爲1.178億美元，合每股虧損1.88美元，而2022年的淨收益爲4,740萬美元，合每股虧損0.76美元。
2023年運營產生的現金流入爲7,470萬美元。
截至2023年底，該公司的現金和投資總額爲1.72億美元。預計2024年2月DRI將額外支付1.16億美元的特許權使用費，到2024年3月，現金和投資總額將增加到2.3億美元。
Business Progress:
業務進展：
Omeros extended its cash runway into 2026 via a $116 million non-dilutive capital arrangement in a royalty deal with DRI Healthcare, with potential to earn an additional total of $55 million in two sales-related milestone payments.
The company obtained FDA approval for drugs narsoplimab and OMS906 to proceed to clinical phases.
Corporate goal is to expedite OMS906, a MASP-2 inhibitor, into a Phase III clinical program.
Positive interim analysis data from OMS906 was derived from PNH patients in the fully enrolled Phase II clinical trials.
A Phase II clinical trial for OMS906 has started for C3G, a dangerous and potentially fatal kidney disease.
Phase III trials for OMS906 and a Phase II program for OMS1029 are expected to commence soon.
Omeros looks forward to enroll in their Phase II C3G trial and the Phase II PNH studies have shown consistently positive data.
After the discontinuation of the narsoplimab Phase III ARTEMIS-IGAN trial in IgA nephropathy, other programs are in progress with a possibility of adding substantial value to shareholders.
Omeros is talking with the FDA about the resubmission process for narsoplimab and HSCT-TMA and the firm's survival analysis.
Omeros通過與DRI Healthcare簽訂的特許權使用費協議中的1.16億美元非稀釋性資本安排，將其現金流延長至2026年，有可能通過兩筆與銷售相關的里程碑付款獲得總額爲5500萬美元的額外收入。
該公司已獲得美國食品藥品管理局批准，允許藥物納索普利單抗和 OMS906 進入臨床階段。
企業目標是加快 MASP-2 抑制劑 OMS906 進入三期臨床計劃。
OMS906 的陽性中期分析數據來自完全入組的 II 期臨床試驗中的 PNH 患者。
針對C3G（一種危險且可能致命的腎臟疾病）的 OMS906 二期臨床試驗已經開始。
OMS906 的三期試驗和 OMS1029 的二期計劃預計將很快開始。
Omeros期待報名參加他們的II期C3G試驗，二期PNH研究顯示出持續的積極數據。
在針對IgA腎病的納索普利單抗三期ARTEMIS-IGAN試驗終止後，其他項目正在進行中，有可能爲股東增加可觀的價值。
奧美羅斯正在與美國食品藥品管理局討論納索普利單抗和HSCT-TMA的重新提交程序以及該公司的存活分析。
More details: Omeros IR
更多詳情： Omeros IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。